Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review.

ABSTRACT:

Objective

This study aimed to conduct a systematic review of preclinical and clinical evidence to chart the successful trajectory of talimogene laherparepvec (T-VEC) from the bench to the clinic.

Design

This study was a systematic review. The primary outcome of interest was the efficacy of treatment, determined by complete response. Abstract and full-text selection as well as data extraction were done by two independent reviewers. The Cochrane risk of bias tool was used to assess the risk of bias in studies.

Setting

Embase, Embase Classic and OvidMedline were searched from inception until May 2016 to assess its development trajectory to approval in 2015.

Participants

Preclinical and clinical controlled comparison studies, as well as observational studies.

In

SUBMITTER: Lalu M 

PROVIDER: S-EPMC7003485 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature